• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Ben-Yedidia Tamar

    1/3/23 3:14:28 PM ET
    $BVXV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BVXV alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Ben-Yedidia Tamar

    (Last) (First) (Middle)
    JERUSALEM BIOPARK, 2ND FLOOR
    HADASSAH EIN KEREM CAMPUS

    (Street)
    JERUSALEM L3 9112001

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/01/2023
    3. Issuer Name and Ticker or Trading Symbol
    BiondVax Pharmaceuticals Ltd. [ BVXV ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientist
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Share Units 09/23/2024 09/21/2031 Ordinary Shares(1) 300,000 (2) D
    Restricted Share Units 10/18/2024 10/16/2031 Ordinary Shares(1) 1,340,000 (2) D
    Restricted Share Units 03/23/2025 03/23/2032 Ordinary Shares(1) 1,500,000 (2) D
    Explanation of Responses:
    1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
    2. Each restricted share unit represents a contingent right to receive one ordinary share.
    /s/ Tamar Ben-Yedidia 01/03/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BVXV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVXV

    DatePrice TargetRatingAnalyst
    1/26/2022$7.00Buy
    Aegis Capital
    More analyst ratings

    $BVXV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Margolin Yael claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:16:22 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Laster Morris C claimed ownership of 66,800 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:10:29 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Lowell George claimed ownership of 421,680 units of Ordinary Shares (Amendment)

      3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)

      1/23/23 8:04:49 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BVXV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital initiated coverage on BiondVax Pharmaceuticals with a new price target

      Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00

      1/26/22 10:21:55 AM ET
      $BVXV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care